Journal of Oriental Neuropsychiatry (동의신경정신과학회지)

The Korean Society of Oriental Neuropsychiatry (대한한방신경정신과학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Problem Behavior in Adult with Severe Intellectual Disability Treated with the Korean Herbal Medicine Yokukan-san-gami (Yigan-san-jiawei)

성인 중증 지적장애에서의 문제행동에 대한 억간산가미(抑肝散加味) 치험 1례 보고

  • Choi, Eun-ji (Department of Korean Neuropsychiatry, Gangdong Kyung Hee University Hospital) ;
  • Suh, Hyo-weon (Department of Clinical Korean Medicine, Graduate School, Kyung Hee University) ;
  • Chung, Sun Yong (Department of Korean Neuropsychiatry, Gangdong Kyung Hee University Hospital) ;
  • Kim, Jong Woo (Department of Korean Neuropsychiatry, Gangdong Kyung Hee University Hospital)
  • 최은지 (강동경희대학교병원 한방신경정신과) ;
  • 서효원 (경희대학교 대학원 임상한의학과) ;
  • 정선용 (강동경희대학교병원 한방신경정신과) ;
  • 김종우 (강동경희대학교병원 한방신경정신과)
  • Received : 2017.11.20
  • Accepted : 2017.12.20
  • Published : 2017.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

This case report presents a 31-year-old male intellectual disability patient with problem behavior such as food refusal and temper tantrums. He was treated with the Korean traditional herbal medicine (Yokukan-san-gami) continuously for 56 days. The effects of the treatment were measured by the frequency of his problem behavior and the score of the Korean version of Aberrant Behavior Checklist (ABC). After treatment, his challenging behavior became reduced, and his ABC score had been decreased by 24.6%. The findings from this case suggest that the Korean traditional herbal medicine (Yokukan-san) could be effective for challenging behavior in patients with intellectual disabilities.

Keywords

References

  1. Min SK. Modern psychiatry. 6th ed. Seoul. Ilchokak. 2015:618-21.
  2. Bowring DL, et al. Challenging behaviours in adults with an intellectual disability: A total population study and exploration of risk indices. Br J Clin Psychol. 2017;56(1):16-32. https://doi.org/10.1111/bjc.12118
  3. Deb S, Thomas M, Bright C. Mental disorder in adults with intellectual disability. 2: The rate of behaviour disorders among a community-based population aged between 16 and 64 years. J Intellect Disabil Res. 2001;45(Pt 6):506-14. https://doi.org/10.1046/j.1365-2788.2001.00373.x
  4. James N. The formal support experiences of family carers of people with an intellectual disability who also display challenging behaviour and/or mental health issues:what do carers say?. J Intellect Disabil. 2013;17(1):6-23. https://doi.org/10.1177/1744629512472610
  5. Tyrer P, Oliver-Africano PC, Ahmed Z, et al. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. Lancet. 2008;371(9606):57-63. https://doi.org/10.1016/S0140-6736(08)60072-0
  6. Rana F, Gormez A, Varghese S. Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities. Cochrane Database Syst Rev. 2013;(4):CD009084.
  7. Ali A, Hall I, Blickwedel J, Hassiotis A. Behavioural and cognitive-behavioural interventions for outwardly-directed aggressive behaviour in people with intellectual disabilities. Cochrane Database Syst Rev. 2015:7;(4):CD003406.
  8. Kim NY, Ko JS, Kim SW, Lee DH, Kim SH, Kim GW. A Case Report on the Communicating Hydrocephalus and Brain Lesions with Mental Retardation. J Oriental Neuropsychiatry. 2013;24(4):403-10. https://doi.org/10.7231/jon.2013.24.4.403
  9. Baek JN. Construct Validity Verification of the Aberrant Behavior Checklist(ABC). J Intellect Disabil. 2015;17(4):1-17.
  10. Aman MG, Singh NN. Aberrant behavior checklist-community. Supplementary manual. East Aurora, NY. Slosson Educational.
  11. Martin J. Brodie,corresponding author Frank Besag, Alan B. Ettinger, et al. Epilepsy, Antiepileptic Drugs, and Aggression: An Evidence-Based ReviewAn external file that holds a picture, illustration, etc. Pharmacol Rev. 2016;68(3):563-602. https://doi.org/10.1124/pr.115.012021
  12. Oliver-Africano P, Murphy D, Tyrer P. Aggressive behaviour in adults with intellectual disability: defining the role of drug treatment. CNS Drugs. 2009;23(11):903-13. https://doi.org/10.2165/11310930-000000000-00000
  13. Miyaoka T, Wake R, Furuya M, et al. Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. BMC Psychiatry. 2012;12:215. https://doi.org/10.1186/1471-244X-12-215
  14. Wake R, Miyaoka T, Inagaki T, et al. Yokukansan (TJ-54) for Irritability Associated with Pervasive Developmental Disorder in Children and Adolescents: A 12-week Prospective, Open Label Study. J Child Adolesc Psychopharmacol. 2013;23:329. https://doi.org/10.1089/cap.2012.0108
  15. Ikarashi Y, Mizoguchi K. Neuropharmacological efficacy of the traditional Japanese Kampo medicine yokukansan and its active ingredients. Pharmacol Ther. 2016;166:84-95. https://doi.org/10.1016/j.pharmthera.2016.06.018
  16. Matsunaga S, Kishi T, Iwata N. Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials. J Alzheimers Dis. 2016;54(2):635-43. https://doi.org/10.3233/JAD-160418
  17. Youn JC, Lee WH, Choi JB. Comparison of Psychometric Properties between the Korean Version of Behavior Rating Scale for Dementia(BRSD) and Neuropsychiatric Inventory(NPI). Kor J Psychopathol. 2008;16,17(1,2):40-8.
  18. Jeanne Lenzer. FDA warns about using antipsychotic drugs for dementia. MJ. 2005;330(7497):922. https://doi.org/10.1136/bmj.330.7482.92-a